Zobrazeno 1 - 10
of 290
pro vyhledávání: ''
Autor:
Ines Beilmann-Lehtonen, Ulf-Håkan Stenman, Caj Haglund, Tuomas Kaprio, Kajsa Björkman, Camilla Böckelman
Publikováno v:
Oncology. 100:22-30
Objectives: Colorectal cancer is the third most common cancer worldwide, with an obvious need for more accurate prognostics. Previous studies identified C-reactive protein (CRP) as a prognostic serum biomarker for colorectal cancer, whereas the bioma
Autor:
Yukio Miki, Kohei Kotani, Kanako Yoshida, Kenjiro Kimura, Naoshi Odagiri, Sawako Uchida-Kobayashi, Akihiro Tamori, Hiroko Ikenaga, Shoji Kubo, Atsushi Hagihara, Ken Kageyama, Masaru Enomoto, Norifumi Kawada, Akira Yamamoto, Hideki Fujii
Publikováno v:
Oncology. 99(3):186-191
Introduction: Lenvatinib has been approved as a systemic therapy for patients with unresectable hepatocellular carcinoma (HCC). We recently experienced lenvatinib-induced tumor-related hemorrhage in patients with HCC. The full details of tumor-relate
Autor:
Alla Berlin, Leora Brazg Ferro, Ester Osher, Orit Gutfeld, Inbal Golomb, Inna Ospovat, Viacheslav Soyfer, Ido Wolf, Shira Peleg Hasson
Publikováno v:
Oncology. 99:373-379
Introduction: Extrapulmonary small-cell cancer (EPSCC) is a relatively rare malignancy. The management of EPSCC is usually extrapolated from small-cell lung cancer (SCLC). In spite of the morphological similarity of the 2 malignancies, there are many
Autor:
Caj Haglund, Tuomas Kaprio, Jaana Hagström, Ines Beilmann-Lehtonen, Karin Strigård, Richard Palmqvist, Ulf-Håkan Stenman, Ulf Gunnarsson, Camilla Böckelman
Publikováno v:
Oncology. 99:790-801
Background: Colorectal cancer (CRC) is the third most commonly diagnosed malignancy globally. CRC patients with elevated plasma C-reactive protein (CRP) levels exhibit compromised prognoses. Toll-like receptors (TLRs), activating the innate and adapt
Autor:
Savtaj S. Brar, Carol Jane Swallow, Charles Henry Lim, Hao-Wen Sim, Jennifer J. Knox, Bryan A. Chan, Akina Natori, James Brierley, Osvaldo Espin-Garcia, Rebecca Wong, Jolie Ringash, Eric Chen, Elena Elimova, Sara Hafezi-Bakhtiari, John Kim, Raymond Woo-Jun Jang, Di Maria Jiang, Geoffrey Liu, Patrik Rogalla, Gail Darling, Stephanie Moignard
Publikováno v:
Oncology. 99:49-56
Background: Trimodality therapy (TMT) with neoadjuvant chemoradiotherapy (nCRT) using concurrent carboplatin plus paclitaxel (CP) followed by surgery is the standard of care for locoregional esophageal or gastroesophageal junction (GEJ) cancers. Alte
Publikováno v:
ONCOLOGY. :407-412
Background Early-phase clinical trials are critical to the advancement of cancer care, especially in patients with pancreatic ductal adenocarcinoma, given its aggressive nature and limited available therapeutic options. Methods A retrospective chart
Autor:
Diana Pettinato, Alfredo Mirandola, Francesca Zanellini, Amelia Barcellini, Marianna Roccio, Francesca Valvo, Ester Orlandi, Angiolo Gadducci, Concetta Laliscia
Publikováno v:
Oncology. 99:65-71
Background and Summary: The management of endometrial cancer, in an ever-older population with considerable comorbidity, remains a challenge for gynecological and radiation oncologists. Key Message: The present paper reviews literature data on treatm
Autor:
Hitomi Sezaki, Yasuji Arase, Kenji Ikeda, Mariko Kobayashi, Fumitaka Suzuki, Tetsuya Hosaka, Yoshiyuki Suzuki, Masahiro Kobayashi, Yusuke Kawamura, Satoshi Saitoh, Shunichiro Fujiyama, Hiromitsu Kumada, Norio Akuta
Publikováno v:
Oncology. 99:114-123
Introduction: It remains unclear whether TERT promoter mutation (TERT C228T) in serum cell-free DNA (cfDNA) is useful for the diagnosis of hepatocellular carcinoma (HCC) in patients with nonalcoholic fatty liver disease (NAFLD). Methods: In this retr
Autor:
Kentaro Ito, Kazutaka Kakinuma, Tadashi Sakaguchi, Naoya Hida, Masamichi Mineshita, Osamu Hataji, Kei Morikawa, Takeo Inoue, Yuko Komase, Naoki Furuya
Publikováno v:
Oncology
Objectives: Currently, combination therapy of ramucirumab (RAM) + docetaxel (DOC) must play a more important role as a second-line treatment. Epithelial growth factor receptor (EGFR) mutation accounts for around 50% of oncogenic driver mutations in p
Autor:
Lin Fung Chan, Hiroshi Miyakita, Seiichiro Yamamoto, Toshiyuki Suzuki, Kazutake Okada, Hiroshi Kajiwara, Sotaro Sadahiro
Publikováno v:
Oncology
Background: In patients with colorectal cancer, the rate of recurrence increases as the histologic stage progresses. However, the prediction of recurrence in individual patients is difficult. Many studies have reported on the relation between outcome